News & Events

Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies. Liu J, Halloran JT, Bilmes JA, Daza RM, Lee C, Mahen EM, Prunkard… Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3… Buparlisib plus fulvestrant in postmenopausal women

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Kim… Ipatasertib plus paclitaxel versus placebo plus paclitaxel

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.… Phase 1/2 trial of ublituximab

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Dirix LY, Takacs I, Jerusalem… Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A,… TITAN: phase III study of doxorubicin/cyclophosphamide

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.… Final overall survival analysis for the phase II RECORD-3